Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma

BACKGROUND: Tyrosine kinase inhibitors (TKI) combined with programmed cell death-1 (PD-1) inhibitor is a potential treatment modality for patients with HCV-related unresectable hepatocellular carcinoma (uHCC). METHODS: The participants of the present work included the patients having HCV-related uHC...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Jin, Yang, Sibo, Chen, Bowen, Zhang, Linzhi, Yan, Tao, Yang, Gangqi, Chen, Yue, Li, Yinyin, Lu, Yinying, Zuo, Shi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987323/
https://www.ncbi.nlm.nih.gov/pubmed/36891505
http://dx.doi.org/10.2147/JHC.S392347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987323/
https://www.ncbi.nlm.nih.gov/pubmed/36891505
http://dx.doi.org/10.2147/JHC.S392347

Ejemplares similares